Abstract: The present invention relates to the field of treatment of diseases. Specifically, the present invention relates to an anti-ROR1 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding same, and methods for preparing same. The anti-ROR1 antibody or the antigen-binding fragment thereof of the present invention has high specificity and high affinity for ROR1, and can effectively bind ROR1 and mediate killing of ROR1 expression cells. Therefore, the present invention further relates to a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, and a use thereof in preparation of a drug which is used for prevention and/or treatment of tumors.

Abstract: Anti-FGFR3 antigen-binding proteins and antigen-binding binding fragments thereof are provided. Methods of inhibiting FGFR3 activity and methods of treating FGFR3-mediated diseases and disorders are also provided.

Abstract: The present disclosure relates generally to immunoglobulin-related compositions (e.g multi-specific antibodies or antigen binding fragments thereof) that can bind to the Claudin 18.2 protein. The multi-specific antibodies of the present technology are useful in methods for detecting and treating a Claudin 18.2-associated cancer in a subject in need thereof.

Abstract: Anti-FGFR3 antigen-binding proteins and antigen-binding binding fragments thereof are provided. Methods of inhibiting FGFR3 activity and methods of treating FGFR3-mediated diseases and disorders are also provided.

Abstract: Anti-FGFR3 antigen-binding proteins and antigen-binding binding fragments thereof are provided. Methods of inhibiting FGFR3 activity and methods of treating FGFR3-mediated diseases and disorders are also provided.

Abstract: Provided herein multispecific (e.g., bispecific) binding molecules comprising a first binding domain that binds an extracellular portion of dystroglycan and a second binding domain that binds laminin-2. Further provided herein are methods for making such binding molecules and uses of such binding molecules for treating and/or preventing alpha-dystroglycanopathies.

Abstract: Provided herein multispecific (e.g., bispecific) binding molecules comprising a first binding domain that binds an extracellular portion of dystroglycan and a second binding domain that binds laminin-2. Further provided herein are methods for making such binding molecules and uses of such binding molecules for treating and/or preventing alpha-dystroglycanopathies.

Abstract: Provided herein multispecific (e.g., bispecific) binding molecules comprising a first binding domain that binds an extracellular portion of dystroglycan and a second binding domain that binds laminin-2. Further provided herein are methods for making such binding molecules and uses of such binding molecules for treating and/or preventing alpha-dystroglycanopathies.

Abstract: Provided herein multispecific (e.g., bispecific) binding molecules comprising a first binding domain that binds an extracellular portion of dystroglycan and a second binding domain that binds laminin-2. Further provided herein are methods for making such binding molecules and uses of such binding molecules for treating and/or preventing alpha-dystroglycanopathies.

Abstract: Osteopontin is a marker for oligodendrocyte precursor cells. Osteopontin also modulates oligodendrocyte differentiation and central nervous system myelination. Osteopontin induces migration of oligodendrocyte precursors.